Baird Medical Successfully Showcases MWA Technology at NASIT 2026

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Mar 09 2026

0mins

BDMD+9.95%

Should l Buy BDMD?

Source: PRnewswire

Successful Strategic Showcase: Baird Medical successfully showcased its Microwave Ablation (MWA) technology at the 2026 North American Society for Interventional Thyroidology (NASIT), reinforcing its market leadership in minimally invasive treatments.
Expanded Patient Access: The showcase aims to enhance patient access to advanced minimally invasive treatment options, indicating the company's commitment to improving healthcare accessibility and quality to meet growing market demand.
Increased Industry Influence: By participating in the NASIT conference, Baird Medical not only demonstrated its technological advantages but also strengthened connections with industry experts and potential partners, facilitating future business development.
Market Strategy Alignment: This event aligns with the company's strategic goal of expanding market share, which is expected to lay the groundwork for future product promotion and market penetration, further driving company growth.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BDMD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on BDMD

About BDMD

Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Baird Medical Successfully Hosts Clinical Training in Indonesia

Mar 16 2026PRnewswire

Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia, aimed at enhancing the skills of local healthcare providers, thereby improving patient care quality and reinforcing its leadership position in the Southeast Asian market.
Market Expansion Strategy: This training initiative is a key part of the company's strategic expansion into Southeast Asia, providing advanced knowledge of Microwave Ablation technology to help healthcare institutions improve treatment outcomes and meet the growing patient demand.
Technology Promotion: Through these workshops, Baird Medical showcased its expertise in minimally invasive technology to Indonesian healthcare providers, aiming to elevate industry standards through education and training, thus increasing market acceptance of its products.
Strengthening Regional Partnerships: The event not only fostered collaboration with Indonesian healthcare institutions but also laid the groundwork for future business expansion, demonstrating the company's commitment and long-term investment intentions in the Southeast Asian market.

Baird Medical Successfully Conducts Clinical Training Workshops in Indonesia

Mar 16 2026Newsfilter

Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia at EKA Medika Hospital and RSCM Hospital, providing local physicians with hands-on experience in Microwave Ablation technology, thereby enhancing the company's influence in the Southeast Asian market.
Strategic Expansion: The workshops not only equipped regional healthcare providers with advanced tools and practical knowledge but also facilitated Baird Medical's strategic expansion in Southeast Asia, which is expected to improve patient care quality and drive business growth.
Market Leadership: As a market leader in minimally invasive diagnostics and treatment, Baird Medical's solutions are utilized in over 30 prestigious hospitals in the U.S., further solidifying its competitive advantage in the global medical device market.
Future Development Vision: Baird Medical is committed to fostering strategic collaborations with leading academic institutions to advance the research and development of surgical robotic systems and innovative minimally invasive surgical instruments, aiming to enhance patient outcomes through precision technology and demonstrate its foresight in medical innovation.

Baird Medical Secures Regulatory Approval in Argentina

Mar 12 2026PRnewswire

International Expansion Milestone: Baird Medical's regulatory clearance in Argentina marks a strategic advancement in its mission to promote Microwave Ablation technology globally, which is expected to significantly enhance the company's competitiveness in international markets.
Enhanced Certification Portfolio: The approval in Argentina enriches Baird Medical's international certification portfolio, which already includes the U.S. FDA, Indonesia, Malaysia, and Vietnam, thereby strengthening its foundation for global business expansion.
Regulatory Pipeline Advancement: The company is actively seeking formal registrations in key markets such as Egypt, Sri Lanka, the Philippines, and Pakistan, demonstrating its commitment to meeting the rising global healthcare demand.
Market Leadership Position: Baird Medical holds a leading position in the thyroid microwave ablation device market in China, and with its products gradually expanding into over 20 countries, it is poised to further solidify its leadership in the global medical device industry.

Baird Medical Secures Regulatory Approval in Argentina

Mar 12 2026Newsfilter

International Expansion Milestone: Baird Medical's regulatory clearance in Argentina marks a significant step in its global growth strategy for Microwave Ablation technology, aimed at enhancing patient access to effective minimally invasive therapies and solidifying its market leadership.
Enhanced Certification Portfolio: The approval in Argentina enriches Baird Medical's international certification portfolio, which now includes the U.S. FDA, Indonesia, Malaysia, and Vietnam, demonstrating the company's robust momentum in global markets.
Regulatory Pipeline Advancement: The company is actively pursuing formal registrations in key markets such as Egypt, Sri Lanka, the Philippines, and Pakistan, ensuring its products meet the rising global demand and enhancing its competitiveness in the international medical device sector.
Strategic Collaboration Vision: Baird Medical is committed to establishing strategic collaborations with leading academic institutions to drive the research and development of minimally invasive diagnostic and treatment technologies, aiming to improve patient outcomes through precision technology and expand its influence in the global healthcare market.